This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moelis & Company's (MC) Q2 Earnings Top as Revenues Rise Y/Y
by Zacks Equity Research
Moelis & Company's (PB) second-quarter earnings beat estimates on the back of higher revenues and other income, given higher transaction completions. However, higher operating expenses hurt.
Goldman Sachs (GS) Q2 Result Out: Should You Make a Bet Now?
by Riya Anand
Goldman Sachs's (GS) strength in IB and trading businesses is positive. Stretched Valuations and escalating costs are a concern. Should investors buy the stock now or wait for a better entry point?
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Raymond James' (RJF) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
A rise in revenues driven by strong IB performance and higher assets under administration balance support Raymond James' (RJF) fiscal Q3 earnings.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Investors Heavily Search Morgan Stanley (MS): Here is What You Need to Know
by Zacks Equity Research
Morgan Stanley (MS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Invest in the Invesco KBW Bank ETF (KBWB)?
by Zacks Equity Research
Sector ETF report for KBWB
Euronet (EEFT) Q2 Earnings Meet, EFT Processing Unit Aids
by Zacks Equity Research
Euronet's (EEFT) Q2 results benefit from a strong merchant acquiring business and solid growth in cross-border transactions. It continues to expect 2024 adjusted EPS to witness 10-15% growth from the 2023 figure.
Stocks to Watch as Trump Picks Running Mate
by Shaun Pruitt
Whether you're an investor who keeps it neutral regarding politics or not, being mindful of policies that may affect certain areas of the economy is still beneficial and sometimes necessary.
Company News for Jul 17, 2024
by Zacks Equity Research
Companies in The News Are: BAC,MS,PNC,FBK
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Should You Invest in the iShares U.S. Broker-Dealers & Securities Exchanges ETF (IAI)?
by Zacks Equity Research
Sector ETF report for IAI
Morgan Stanley (MS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Morgan Stanley (MS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Retail Sales Came in Better Than Expected
by Zacks Equity Research
Retail Sales Came in Better Than Expected
Econ Reports, Q2 Earnings Take July Rate Cut Off the Table
by Mark Vickery
Any investors still hoping for a July rate cut based on economic prints, we can uncross our fingers now.
Morgan Stanley (MS) Q2 Earnings Beat on Robust IB & Trading
by Zacks Equity Research
The resurgence of the capital markets businesses majorly supports Morgan Stanley's (MS) Q2 earnings, while the muted wealth management business acts as a spoilsport.
Morgan Stanley (MS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Morgan Stanley (MS) delivered earnings and revenue surprises of 10.30% and 5.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dow Closes at New High as Q2 Earnings Season Heats Up
by Mark Vickery
Earnings season only picks up steam in the weeks to come.
A Big Week in the USA: Global Week Ahead
by John Blank
Inflation and higher rates have tested the resilience of households as signs of a cooling economy and inflation bolster expectations for rate cuts to start in September.
IB, Trading to Support Morgan Stanley's (MS) Q2 Earnings
by Zacks Equity Research
Morgan Stanley's (MS) second-quarter 2024 earnings are expected to have been positively impacted by a decent trading performance.
Morgan Stanley (MS) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Morgan Stanley (MS) closed at $104.09, indicating a -0.53% shift from the previous trading day.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
by Zacks Equity Research
Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.
Morgan Stanley (MS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Morgan Stanley (MS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Top Analyst Reports for Danaher, Morgan Stanley & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Morgan Stanley (MS) and Pfizer Inc. (PFE), as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. (ELTP) and Oil-Dri Corporation of America (ODC).